DTRA Archives - EverGlade Consulting

DTRA

Advancing Biodefense Readiness: MTEC and DTRA’s Multi-Topic RPP

In September 2025, the Medical Technology Enterprise Consortium (MTEC), in partnership with the Defense Threat Reduction Agency (DTRA), announced a new Request for Project Proposals (RPP) aimed at accelerating U.S. biodefense capabilities. The solicitation, “Advancing Biodefense Readiness: On-Demand Biologics, Automated Threat Detection, and Alternatives for Testing Medical Countermeasures in High Containment,” seeks applied prototype solutions […]

Advancing Biodefense Readiness: MTEC and DTRA’s Multi-Topic RPP Read More »

DTRA–MTEC Pre-Announcement for Biodefense Readiness RPP

MTEC-25-DTRA Pre-Announcement: Advancing Biodefense Readiness The Medical Technology Enterprise Consortium (MTEC), in support of the Defense Threat Reduction Agency (DTRA), has issued a pre-announcement for an upcoming Request for Project Proposals (RPP). This RPP will be aimed at accelerating medical countermeasures (MCMs) and fieldable biosurveillance technologies across the Chemical and Biological Defense Program. In brief,

DTRA–MTEC Pre-Announcement for Biodefense Readiness RPP Read More »

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models

Advancing Countermeasures for Marine Toxin Threats The Defense Threat Reduction Agency (DTRA), through its Research and Development Chemical and Biological Technologies Directorate in support of the Joint Science and Technology Office (JSTO), has issued a Request for Information (RFI) titled “Plume”. This initiative seeks information on the capabilities and availability of suitable animal models for

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models Read More »

DTRA RAVEN Program

DTRA’s Reimagining the Next Generation of Biodefense Vaccines

Reimagining the Next Generation of Biodefense Vaccines: DTRA’s RAVEN Opportunity The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO) and the Research and Development-Chem/Bio Medical Vaccines (RD-CBMV) division, has launched the Reimagining Available Vaccines and Envisioning Novelty (RAVEN) initiative. This forward-looking program is designed to modernize the nation’s medical countermeasure

DTRA’s Reimagining the Next Generation of Biodefense Vaccines Read More »

organophosphorus nerve agents

Project UPREG

Project UPREG: DTRA’s Push for Enhanced Protection Against Nerve Agents The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO), has launched Project UPREG, a bold initiative to develop next-generation medical countermeasures against organophosphorus nerve agents (OPNAs). These highly toxic compounds pose a

Project UPREG Read More »

handheld diagnostic device

Assay Expansion for Chemical Diagnostic System

Assay-Expansion-for-Chemical-Diagnostics-System-SOO_Final The Defense Threat Reduction Agency’s Medical Diagnostics Branch (RD-CBMD) is driving innovation with its 2026 solicitation to expand the ChemDx platform. ChemDx is a handheld diagnostic device for rapid detection of chemical threats, such as nerve agents or certain pesticides, in blood from a finger prick. This effort seeks proposals from organizations interested in

Assay Expansion for Chemical Diagnostic System Read More »

technology to identify novel antigens

DTRA MCDC RAIIC Funding Opportunity

Final-draft-SOO-RAIIC The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC) to develop technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID). JSTO intends to incorporate the final technology into

DTRA MCDC RAIIC Funding Opportunity Read More »

compact wearable vaccine monitoring

DTRA Issues Draft SOO for Continual Blood Sampling Technology

Final-Draft-SOO-IMMIR The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC). The objective of the IMMIR solicitation is to develop innovative technologies for vaccine monitoring via a compact wearable device that can analyze minute blood samples.

DTRA Issues Draft SOO for Continual Blood Sampling Technology Read More »

medical countermeasures

DTRA Issues SOO for Broad-Spectrum Therapeutics

August-24-Broad-Spectrum-SOO The Defense Threat Reduction Agency (DTRA) has released a Statement of Objectives (SOO) to develop  prototype Medical Countermeasures (MCMs) aimed at addressing therapeutic indications of Warfigher exposure to viral and bacterial biothreat agents. Key Information and Deadlines The Project Agreement Holder must state if their proposal is for the solution of the objecties of

DTRA Issues SOO for Broad-Spectrum Therapeutics Read More »

Scroll to Top